Kesoram Industries shares ended 13.14 per cent up at Rs 125.25 after rating agency Credit Analysis & Research Ltd (CARE) revised long/short-term bank facilities of Kesoram Industries from CARE A minus to CARE A2 plus and removed it from credit watch.
The BSE Sensex and NSE Nifty ended nearly a percentage point down on Thursday following their global counterparts. Sensex closed below 27,000-mark by plunging 257.20 points to end at 26,763.46m, while Nifty tumbled 69.45 points to settle at 8,203.60.
Below are 10 stocks are in focus in Thursday’s trade
Kesoram Industries: Shares of the company ended 13.14 per cent up at Rs 125.25 after rating agency Credit Analysis & Research Ltd (CARE) revised long/short-term bank facilities of Kesoram Industries from CARE A minus to CARE A2 plus and removed it from credit watch.
Infosys: Shares of the company ended 4.27 per cent down at Rs 1185.45 after company’s COO Pravin Rao reportedly said that the company would face volatility over the next few quarters due to weaker spending from sectors such as energy and insurance.
Lupin: Share price of the company ended 0.18 per cent down at Rs 1427.95 as it is recalling over 54,000 vials of anti-bacterial injection Ceftriaxone manufactured at its Mandideep facility in Madhya Pradesh due to violation of current good manufacturing norms.
Eros International Media: Shares of the comapny ended 4.44 per cent up at Rs 215.10 after its latest Bollywood flick Housefull 3 garnered over Rs 100 crore across the globe and its on-demand entertainment platform Eros Now inked a deal with Apple TV for showcasing its repository of films and music videos across 80 countries.
Dr Reddy’s Laboratories: Shares of the company ended 1.95 per cent down at Rs 3071.45 after reports that the US Consumer Product Safety Commission charges company for packaging lapses in at least five prescription drugs.
Granules India: Stocks of the pharma company ended 1.68 per cent up at Rs 142.10 after its subsidiary, Granules Pharmaceuticals Inc, entered into a product in-licensing pact with USpharma Windlas, LLC to market and distribute four products in the US.